Guide
Guidelines on long-acting injectable cabotegravir for HIV prevention
External resource. Not made or verified by Public Protocol.
WHO guidelines of July 2022 stating that long-acting injectable cabotegravir may be offered as an additional HIV prevention option for people at substantial risk.
https://www.who.int/publications/i/item/9789240054097
- Maintainer
- World Health Organization
- Licence, as stated at its source
- CC BY-NC-SA 3.0 IGO
- Open or commercial
- Open
- Maturity
- EstablishedOur reading, 16 November 2026
- Safety
- S3medical
- Review
- Listed 16 November 2026by Public Protocol editors
- Checked
- 16 November 2026
- Next check due
- 16 May 2027
- Steward
- Public Protocol editors
Where it sits in the blueprint
- Domains
- Stages
Learn
- Elements it supports
Recorded when its maker or a reviewer places it against single elements.
- Context
Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.
Verification
No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.
Record
- How it came in
Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.
- Licence
CC BY-NC-SA 3.0 IGO. Read at https://www.who.int/publications/i/item/9789240054097. How licences are recorded
- Something wrong?